CMPX
Compass Therapeutics, Inc.
$1.83
+1.10%
2026-05-08
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Key Fundamentals
Forward P/E
-4.57
EPS (TTM)
$-0.40
ROE
-45.9%
Profit Margin
0.0%
Debt/Equity
5.25
Price/Book
1.68
Beta
0.67
Market Cap
$335.0M
Avg Volume (10D)
29.2M
Recent Breakout Signals
No recent breakout signals detected for CMPX.
Recent Price Range (60 Days)
60D High
$6.84
60D Low
$1.61
Avg Volume
6.7M
Latest Close
$1.83
Get breakout alerts for CMPX
Sign up for Breakout Scanner to receive daily notifications when CMPX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Compass Therapeutics, Inc. (CMPX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CMPX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CMPX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.